Published in Lab Business Week, September 23rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Elite Pharmaceuticals, Inc.
Report 1: Elite Pharmaceuticals, Inc. (AMEX: ELI) provided an update on the progress of the Company at the annual shareholders meeting on June 26, 2007. A review of recent key accomplishments and a product pipeline status are provided below.
Abuse Resistant Oxycodone - ELI-216
The Company continues to advance ELI-216 forward in its developmental program. This product is a patent-pending opioid abuse deterrent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.